SG10201704214VA - Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases - Google Patents

Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

Info

Publication number
SG10201704214VA
SG10201704214VA SG10201704214VA SG10201704214VA SG10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA
Authority
SG
Singapore
Prior art keywords
oncology
antibodies
extended
life
treatment
Prior art date
Application number
SG10201704214VA
Inventor
Michael Bowen
Herren Wu
William Dall'acqua
Peter Kiener
Bahija Jallal
Anthony Coyle
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG10201704214VA publication Critical patent/SG10201704214VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
SG10201704214VA 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases SG10201704214VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14810609P 2009-01-29 2009-01-29
US18418209P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
SG10201704214VA true SG10201704214VA (en) 2017-06-29

Family

ID=42396023

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2014007637A SG2014007637A (en) 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
SG2011046265A SG172354A1 (en) 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
SG10201704214VA SG10201704214VA (en) 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2014007637A SG2014007637A (en) 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
SG2011046265A SG172354A1 (en) 2009-01-29 2010-01-29 Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

Country Status (14)

Country Link
US (3) US20120034212A1 (en)
EP (1) EP2391384A4 (en)
JP (3) JP2012516158A (en)
KR (1) KR20110108398A (en)
CN (2) CN102387814A (en)
AU (1) AU2010208125B2 (en)
BR (1) BRPI1007005A2 (en)
CA (1) CA2749200A1 (en)
HK (1) HK1201847A1 (en)
MX (1) MX337590B (en)
RU (2) RU2011135422A (en)
SG (3) SG2014007637A (en)
WO (1) WO2010088444A1 (en)
ZA (2) ZA201104796B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US20120034212A1 (en) * 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2473528B1 (en) * 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
AU2011349049B2 (en) * 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
BR112013018932B1 (en) 2011-02-10 2020-11-17 Roche Glycart Ag mutant interleukin-2 (il-2) polypeptide, immunoconjugate, isolated polynucleotide, host cell of microorganisms, method of producing a mutant il-2 polypeptide, pharmaceutical composition and uses of the mutant il-2 polypeptide or immunoconjugate
CA2827581A1 (en) 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
EA201892619A1 (en) * 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI812924B (en) 2011-09-30 2023-08-21 日商中外製藥股份有限公司 Antigen-binding molecules that promote antigen disappearance
CN104093424A (en) 2011-09-30 2014-10-08 中外制药株式会社 Antigen-binding molecule inducing immune response to target antigen
SG11201405137QA (en) 2012-02-24 2014-12-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
ES2662020T3 (en) * 2012-10-22 2018-04-05 Fountain Biopharma Inc. Antibodies against interleukin-6 and its uses
AU2013334740A1 (en) * 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
US10772940B1 (en) * 2012-12-11 2020-09-15 University Of Kentucky Research Foundation Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same
WO2014096672A1 (en) * 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
FR2999431B1 (en) * 2012-12-17 2016-03-18 Lfb Biotechnologies USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS
RU2701684C2 (en) * 2013-10-31 2019-09-30 Ридженерон Фармасьютикалз, Инк. Competitive ligand binding assay for detecting neutralizing antibodies
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
UA122673C2 (en) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Improved il-6 antibodies
JP2018529756A (en) * 2015-07-31 2018-10-11 メディミューン リミテッド Methods for treating hepcidin-mediated disorders
JP2019510078A (en) * 2016-02-23 2019-04-11 セセン バイオ, インコーポレイテッド IL-6 antagonist preparation and use thereof
EP3440108A4 (en) * 2016-04-07 2020-01-08 Janssen Biotech, Inc. Treatment of depression using agents that block binding of il-6 to il-6 receptor
WO2018144773A1 (en) * 2017-02-01 2018-08-09 Yale University Treatment of diuretic resistance
CA3087699A1 (en) * 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
TW202019956A (en) 2018-07-24 2020-06-01 美商麥迪紐有限責任公司 Antibody directed against s. aureus clumping factor a (clfa)
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
AU2019359207A1 (en) 2018-10-09 2021-05-20 Humabs Biomed Sa Antibodies directed against Staphylococcus aureus leukotoxins
JP2022524420A (en) 2019-03-13 2022-05-02 メディミューン,エルエルシー Reduction of Staphylococcus aureus infections in colonized patients
WO2020223565A1 (en) 2019-05-01 2020-11-05 Corvidia Therapeutics, Inc. Anti-il-6 antibody formulation
CN111057152B (en) * 2019-12-11 2022-03-11 中国人民解放军第四军医大学 Anti-human IL-6Ra monoclonal antibody and application thereof
US20230293636A1 (en) * 2019-12-31 2023-09-21 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain
WO2021186398A1 (en) 2020-03-19 2021-09-23 Medimmune Limited Anti-klebsiella pneumoniae antibodies and uses thereof
EP4153312A1 (en) 2020-05-17 2023-03-29 AstraZeneca UK Limited Sars-cov-2 antibodies and methods of selecting and using the same
AR122933A1 (en) 2020-07-10 2022-10-19 Novo Nordisk As METHODS TO TREAT CARDIOVASCULAR DISEASE
CN116234577A (en) 2020-08-10 2023-06-06 阿斯利康(英国)有限公司 SARS-COV-2 antibodies for the treatment and prevention of COVID-19
TW202342095A (en) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 Composition for treatment and prevention of covid-19
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2024073718A1 (en) * 2022-09-30 2024-04-04 Sonnet BioTherapeutics, Inc. Low dose il-6 formulations and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297083B6 (en) * 1998-03-17 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Agent for prevention and treatment of inflammatory intestinal disease containing IL-6 antagonist as active component
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (en) * 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
ES2263984T3 (en) * 2002-06-28 2006-12-16 Domantis Limited DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE.
SI2335725T1 (en) * 2003-04-04 2017-01-31 Genentech, Inc. High concentration antibody and protein formulations
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
JO3058B1 (en) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
EP1896503B1 (en) * 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
WO2007005612A2 (en) * 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2004690A2 (en) * 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
BRPI0811466A2 (en) * 2007-05-07 2014-10-14 Medimmune Llc ISOLATED ANTIBODY, NUCLEIC ACID, VECTOR, ISOLATED CELL, METHODS FOR PRODUCTING AN ANTIBODY, TO TREAT DISEASE OR DISORDER, TO TREAT OR PREVENT REJECTION IN A HUMAN TRANSPLANT PATIENT TO BE TURNED TO HUMAN, TO EXHAUST T CELLS EXPRESSING ICOS IN A HUMAN PATIENT, TO BREAK THE GERMINAL CENTER ARCHITECTURE IN A PRIMARY SECONDARY LYMPHID ORGAN, TO DEPLETE GERMAN CENTRAL LYMPHIDE ORGAN B CELLS WITH A PRIMATE BULTA IN CURRENT CLASSES IN A PRIMATE, AND, PHARMACEUTICAL COMPOSITION.
HUE043782T2 (en) * 2007-05-21 2019-09-30 Alderbio Holdings Llc Antibodies to il-6 and use thereof
JP5513380B2 (en) * 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド Composition of specific binding agents for hepatocyte growth factor
AU2008268362A1 (en) * 2007-06-26 2008-12-31 Medimmune, Llc Methods of treating RSV infections and related conditions
US20120034212A1 (en) * 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases

Also Published As

Publication number Publication date
US20120034212A1 (en) 2012-02-09
CA2749200A1 (en) 2010-08-05
WO2010088444A1 (en) 2010-08-05
BRPI1007005A2 (en) 2016-03-22
SG172354A1 (en) 2011-07-28
JP2012516158A (en) 2012-07-19
KR20110108398A (en) 2011-10-05
HK1201847A1 (en) 2015-09-11
US20170101468A1 (en) 2017-04-13
AU2010208125B2 (en) 2015-02-12
RU2011135422A (en) 2013-03-10
MX2011007832A (en) 2011-10-06
MX337590B (en) 2016-03-11
US20140302058A1 (en) 2014-10-09
JP2017206519A (en) 2017-11-24
CN102387814A (en) 2012-03-21
SG2014007637A (en) 2014-03-28
ZA201104796B (en) 2018-11-28
EP2391384A1 (en) 2011-12-07
EP2391384A4 (en) 2012-12-26
CN104119438A (en) 2014-10-29
JP2016019517A (en) 2016-02-04
RU2650594C1 (en) 2018-04-17
ZA201207249B (en) 2013-08-28
AU2010208125A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
ZA201104796B (en) Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology,autoimmune diseases and inflammatory diseases
EP2068925A4 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ZA201109384B (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
ZA201100974B (en) Treatment of autoimmune and inflammatory disease
HK1245119A1 (en) Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
IL222006A (en) Conjugates of pyrrolobenzodiazepines and their use in therapy
SI2254870T1 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
IL220899A (en) Anti-cd127 antibody and use thereof in the treatment of a subject afflicted with an autoimmune or inflammatory disease
LT2262778T (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
PL2683826T3 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
HK1148271A1 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 1--3- mcp-1 cx3cr1
HK1168283A1 (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1
GB2460178B (en) Depsipeptides and their therapeutic use
EP2420515A4 (en) Diagnosis and treatment of cancer using anti-tmprss11e antibody
GB2460181B (en) Depsipeptides and their therapeutic use
HRP20151393T8 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB0905970D0 (en) Depsipeptides and their therapeutic use
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
PL2265279T3 (en) Use of the nonapeptide pat in the treatment of autoimmune diseases
GB2460180B (en) Depsipeptides and their therapeutic use
GB0809324D0 (en) Depsipeptides and their therapeutic use
GB0809330D0 (en) Depsipeptides and their therapeutic use
GB0809328D0 (en) Depsipeptides and their therapeutic use